Convergent and criterion validity of PROMIS anxiety measures relative to six legacy measures and a structured diagnostic interview for anxiety in cancer patients

Kerrie Clover1,2, Sylvie D. Lambert3, Christopher Oldmeadow4, Benjamin Britton2, Alex J. Mitchell5, Gregory Carter1,2 and Madeleine T. King6*

Abstract

Background: Detecting anxiety in oncology patients is important, requiring valid yet brief measures. One increasingly popular approach is the Patient Reported Outcomes Measurement Information System (PROMIS); however, its validity is not well established in oncology. We assessed the convergent and criterion validity of PROMIS anxiety measures in an oncology sample.

Methods: 132 oncology/haematology outpatients completed the PROMIS Anxiety Computer Adaptive Test (PROMIS-A-CAT) and the 7 item (original) PROMIS Anxiety Short Form (PROMIS-A-SF) along with six well-established measures: Hospital Anxiety and Depression Scale-Anxiety (HADS-A); Generalised Anxiety Disorder-7 (GAD-7); Depression, Anxiety and Stress Scale-Anxiety (DASS-A) and Stress (DASS-S); Distress Thermometer (DT) and PSYCH-6. Correlations, area under the curve (AUC) and diagnostic accuracy statistics were calculated with Structured Clinical Interview as the reference standard.

Results: Both PROMIS measures correlated with all legacy measures at \( p < .001 \) (Rho = .56–.83). AUCs (> .80) were good for both PROMIS measures and comparable to or better than all legacy measures. At the recommended mild cut-point (55), PROMIS-A-SF had sensitivity (.67) comparable to or better than all the legacy measures, whereas PROMIS-A-CAT sensitivity (.59) was lower than GAD-7 (.67) and HADS-A (.62), but comparable to PSYCH-6 and higher than DASS-A, DASS-S and DT. Sensitivity for both was .79. A reduced cut-point of 51 on both PROMIS measures improved sensitivity (.83–.84) although specificity was only adequate (.61–.62).

Conclusions: The convergent and criterion validity of the PROMIS anxiety measures in cancer populations was confirmed as equivalent, but not superior to, established measures (GAD-7 and HADS-A). The PROMIS-A-CAT did not demonstrate clear advantages over PROMIS-A-SF.

Keywords: Cancer, Anxiety, Validation study, Anxiety disorders, Psycho-oncology, Psychology, Patient-reported outcome measures, Reproducibility of results, Surveys and questionnaires

Plain English summary

Many people with cancer suffer needlessly from intense anxiety, since anxiety can be treated. However, in order to be treated, anxiety has to be recognised. Asking people to fill-in a questionnaire about their feelings is one way to let their health care team know if they feel overly...
anxious. This can lead to a conversation about their feelings, support, and treatment.

The question for this study is – which questionnaire should we use? Many questionnaires try to measure anxiety, but none is perfectly accurate. A group of North American researchers (the PROMIS group), have used advanced techniques as a new way of developing questionnaires. We tested whether these new, PROMIS anxiety questionnaires were accurate for people with cancer.

We used a gold standard comparison—an interview by a psychologist. We also compared the new questionnaires to six well-established questionnaires. We found the PROMIS anxiety questionnaires were accurate, but that they were not better (more accurate or shorter) than two existing measures. We also found that the mathematical models used to score the PROMIS anxiety questionnaires might need adjusting for people with cancer.

**Background**

Addressing psychosocial concerns is a well-established standard of care in cancer [1]. Anxiety disorders are common among people with cancer, with prevalence estimates ranging from 18 to 30% [2–6]. Untreated anxiety disorders can have multiple clinical consequences and effective treatments are available [7].

To treat anxiety disorders, they must first be detected [8, 9]. Several validated patient-reported outcome measures (PROMs) for anxiety have been used in oncology; however, none has demonstrated perfect accuracy, leaving scope to develop new measures. One comprehensive approach to developing new PROMs is the PROMIS initiative (8), which applied item-response theory to create patient-reported outcome measures. For anxiety, two types of PROMIS measures are available: “short form” (PROMIS-A-SF) measures in the traditional format and a measure using computer adaptive technology (CAT) (PROMIS-A-CAT). There are several short-form options (2, 4, 6 and 8 items) along with an original, seven-item version and users can also create their own short forms [10]. Longer measures achieve higher correlations with the full item bank, but all versions have highly similar precision and reliability [10]. CAT offers the benefit of tailoring item presentation depending on the patient’s prior responses, reducing response burden by enabling the smallest possible number of items to be used to achieve a specified degree of precision [11].

PROMIS measures are increasingly used in oncology [12], with a recent systematic review identifying 31 studies that used the PROMIS anxiety measures as PROs [12]. However, the concurrent and criterion validity of the PROMIS anxiety measures has not been fully established in oncology populations. A few studies have reported concurrent validity against anxiety-specific ‘legacy’ PROMs, that is, validated measures that preceded PROMIS. We found two studies that used the PROMIS-A-CAT in oncology [13, 14]; however, neither included legacy measures, or reported on CAT functioning.

Three studies have supported the convergent validity of PROMIS-A-SF measures, by finding moderate correlations with mental-health-related legacy measures in oncology samples [15–17]. Quach [15] reported moderate correlations between a five-item version of the PROMIS-A-SF and a prostate-cancer specific anxiety questionnaire (.44) and a general mental health summary questionnaire (.59). Wilford [16] reported moderate correlations (.45–.66) between the PROMIS-A-SF (7 item) and three of four general measures of mental health (FACT emotional wellbeing, Impact of Events and Perceived Stress) and a strong (.72) correlation with the remaining instrument (Brief Symptom Inventory). Sikorski [17] also reported a moderate correlation (approximately 0.60) between the State Anxiety questionnaire and a four-item PROMIS-A-SF measure.

In terms of criterion validity, five studies examined the diagnostic accuracy of PROMIS anxiety measures, using structured clinical interviews as the reference standard [18–22]; however, none were in oncology. Four used the PROMIS-A-SF (8-item version) [18–21] and one used the full item bank (29 items) [22]. No study used the PROMIS-A-CAT. Criterion validity of the PROMIS-A-SF was supported [18–21] with “acceptable” areas under the curve (AUCs) (.85–.86). Similar AUCs were obtained for the GAD-7 and HADS-A, indicating that PROMIS-A-SF had similar performance to these legacy measures. Recommended optimal cut-points on the PROMIS-A-SF varied, from 55 to 60.

As none of these studies involved an oncology sample and none used the PROMIS-A-CAT, further validation of the PROMIS anxiety SF and CAT measures in oncology populations is warranted.

**Aims**

Our primary aim was to examine the criterion validity of the PROMIS-A-SF and PROMIS-A-CAT among oncology outpatients by comparison with structured interview diagnosis of Any Anxiety Disorder. Our second aim was to assess the convergent validity of the PROMIS anxiety measures relative to six legacy measures of anxiety and emotional distress. Our third aim was to describe the functioning of the PROMIS-A-CAT.

**Methods**

**Patients and setting**

A convenience sample of 132 oncology outpatients was recruited from a regional Australian cancer centre. All patients attending for cancer care were eligible, with the
following exclusion criteria: first clinic visit; insufficient English language skills; too unwell to consider participation, in the opinion of the clinic nurse. Ethics Committee approval was obtained (Reference 09/11/18/5.09). Depression measures were also administered, to examine the criterion and convergent validity of PROMIS depression measures, which have previously been reported [23].

Procedure
Patients were approached in the clinic waiting room. Consenting participants returned to complete a structured diagnostic interview conducted by a Registered Psychologist, who then introduced a different staff member to independently facilitate patient completion of the legacy measures, using the QUICATOUCH platform [24], followed by PROMIS measures on the Assessment Centre platform [25].

Measures
Two PROMIS anxiety measures (PROMIS-A-CAT and PROMIS-A-SF) and six legacy measures were administered to all participants. Legacy measures were three measures of anxiety (GAD-7, HADS-A, DASS-A); one stress measure (DASS-S); and two emotional distress measures (Distress Thermometer, PSYCH-6), and were presented in fixed order (DT, GAD-7, PSYCH-6, HADS, DASS). Higher scores indicated more severe symptoms on all measures.

PROMIS measures
Both PROMIS measures record the frequency of symptoms over the past seven days on a five-point response scale (0–4).

PROMIS Anxiety CAT (PROMIS-A-CAT) The PROMIS-A-CAT selects items from a 29-item bank [25], focusing on fear, worry, dread, hyperarousal (tension, restlessness) and somatic arousal (cardiovascular symptoms, dizziness). The PROMIS default settings for standard error (0.3) and maximum number of items (12) were used and the minimum number of responses was changed to one item (from the default of four) to allow the lowest possible number of items to be asked. The Assessment Centre website was used to administer the CAT (using the full 29-item bank) and transform the raw, summed scale scores into T-Scores using norms (mean = 50, standard deviation (SD) = 10) [11].

PROMIS Anxiety Short Form (PROMIS-A-SF) We used version 1 of the PROMIS-A-SF, a seven-item subset of the PROMIS-CAT 29-item bank. Item scores were summed to obtain the total raw score which was then converted to a T-score (mean 50, SD = 10) [26] and rounded to the nearest digit for ease of reporting. A minimum of six completed items was required and in this case, the total score was imputed following instructions in the PROMIS scoring guide [27] (http://nihpromis.org/measures, accessed Nov 2013).

To examine diagnostic accuracy, T-scores from both measures (PROMIS-A-CAT and PROMIS-A-SF) were categorised into severity level using cut-points recommended for the PROMIS total item bank [28] as follows: normal 0–54; mild 55–64; moderate 65–74 and 75+ severely symptomatic.

Legacy anxiety and distress measures
The GAD-7 was developed to measure Generalised Anxiety Disorder (GAD) symptoms [29] and also has established diagnostic accuracy for panic disorder, social anxiety and PTSD [30]. It is a seven-item scale, with each item rated from zero (none of the days) to three (nearly every day) over the past two weeks, giving a response range of 0–21 (PHQ Instruction Manual https://www.phqscreeners.com/images/sites/g/files/g10016261/f/201412/instructions.pdf). Recommended cut-points are 5–9 (mild), 10–14 (moderate) and 15 or more (severe). A score of 10 or more is considered an appropriate cut-point for screening for anxiety disorders. Cronbach’s alpha for the GAD in this sample was 0.93.

The Hospital Anxiety and Depression Scale (HADS) is a 14 item measure, including a seven item anxiety subscale (HADS-A), that has been widely used in oncology [31–33]. Items are rated by how often they occurred over the past two weeks, with zero indicating less of the time and three indicating more of the time (response range 0–21). Possible anxiety is indicated by a score of 8–10, with a score of 11 or more indicating probable anxiety [33]. Cronbach’s alpha was 0.88.

The anxiety (DASS-A) and stress (DASS-S) subscales of the Depression Anxiety and Stress Scale (DASS) are seven-item sub-scales of the 21 item DASS scale. Each item is rated on a four-point scale, from 0, (did not apply to me at all) to 3 (applied to me very much, or most of the time) over the past week [34]. The sub-scale score is doubled for categorisation (range 0–42). Anxiety symptoms are categorised as mild (8–9); moderate (10–14); severe (15–19) and extremely severe (20 and over); stress symptoms are categorised as mild (15–18); moderate (19–25); severe (26–33) and extremely severe (34 and over). Cronbach’s alpha for DASS-A was 0.78 and for DASS-S was 0.90.

The PSYCH-6 is the six-item psychological symptom subscale of the Somatic Psychological Health Report (SPHERE) [35]. Respondents indicate how often items have troubled them over the past few weeks from zero (some of the time or never) to two, (most of the time),
(response range 0–12). We have previously established a cut-point score of three or more for oncology outpatients [35]. Cronbach’s alpha was 0.93. The Distress Thermometer (DT) is a one-item rating of distress over the past week on a 0–10 scale with an established cut-point score of four or more [36].

**Structured diagnostic interview**

The reference standard was the Anxiety Disorders module of the Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID) to assess whether respondents met criteria (present vs absent or sub-threshold) in the past month for Any Anxiety Disorder: Panic Disorder; Agoraphobia; Social Phobia; Specific Phobia; Obsessive–Compulsive Disorder; Posttraumatic Stress Disorder or Generalized Anxiety Disorder.

The interview was conducted by one of two trained, Registered Psychologists with experience in adult mental health. Training followed SCID recommendations, with private study, videotape training, role-play and inter-rater comparisons of a video tape to ensure proficiency [37]. Training was supervised by a Clinical Psychologist (BB) with extensive experience in psycho-oncology. The SCID interviewers were blind to participants’ responses on the self-report measures.

**Statistical analysis**

Analyses used Stata V14 (Statacorp, College Station, TX) and Statistical Package for the Social Sciences 22.0.

**Criterion Validity**

*Area Under the Curve (AUC)* To address our primary aim, we conducted ROC analysis using a SCID diagnosis of Any Anxiety Disorder in the past month as the reference standard, calculating AUC to determine each measure’s performance. AUC were classified as: > 0.70 = ‘useful’; > 0.80 = ‘good’ and > 0.90 = ‘very good’ [38]. Results for each legacy measure at recommended cut-points were calculated to provide a context for interpreting the performance of the PROMIS measures.

*Measures of diagnostic accuracy* For the PROMIS-A-CAT and PROMIS-A-SF, we calculated sensitivity, specificity, negative predictive value (NPV) and positive predictive (PPV) at the T score cut-points for mild (55) and moderate (65) anxiety proposed by Cella et al. [28]. Too few people were classified with severe anxiety to warrant analysis. To examine cut-points we used Youden’s Index, a commonly used summary measure of sensitivity and specificity [39] ranging from zero to one, where one represents perfect performance. Youden’s index assumes equal importance of sensitivity and specificity and therefore may not be optimal for anxiety screening programs [40], which might give higher weight to sensitivity, so that cases are not missed. Nevertheless, we used it to allow comparison with previous studies [18–21].

**Convergent validity**

To address our second aim, two series of bivariate (Spearman) correlations were calculated, comparing the legacy measures with the PROMIS-A-CAT T-Score and PROMIS-A-SF T-Score, respectively. Correlations were classified as weak (< .4), moderate (.4 to < .7) and strong (.7–1) [41]. Spearman’s correlation was chosen as data were non-normal.

**PROMIS-A-CAT functioning**

Our final aim was addressed with descriptive statistics: mean and range of PROMIS-A-CAT scores by SCID diagnosis group (Any Anxiety Disorder vs none); mean and range of number of items administered by the PROMIS-A-CAT for the total sample, by SCID diagnosis (Any Anxiety Disorder vs none) and by PROMIS-A-CAT anxiety severity categories [28].

**Results**

**Sample**

Of 322 eligible people indicating initial interest, 168 attended for data collection, 139 of these commenced the PROMIS measures (PROMIS measures were added some weeks after initial recruitment began) and 132 contributed to this analysis with data from the SCID Anxiety module plus at least one PROMIS measure and at least one legacy measure. The SCID interview took a median of 28 min (IQR 20–35); median time to complete legacy measures was 29 min (IQR 18–53) and 13 min (IQR 11–17) for PROMIS measures.

The sample was predominantly female (69%) and married (68%) (Table 1). Time since diagnosis ranged from five weeks to 21 years (median = 74 weeks).

**SCID diagnosis**

Thirty seven (28%) participants met criteria for Any Anxiety Disorder in the past month on the SCID (Table 1). The most common anxiety diagnoses were GAD (11%); specific phobia (10%) and social phobia (8%). Ten (8%) participants met criteria for more than one anxiety disorder.

**Criterion validity**

*AUC*

AUC were in the ‘good’ range for the PROMIS-A-CAT (0.82, 95%CI = 0.73–0.90) and PROMIS-A-SF (0.80, 95%CI = 0.71–0.89) (Table 2). The AUC for the GAD-7
Diagnostic accuracy statistics

ROC curves for all measures (Fig. 1) provide context for interpreting PROMIS measures’ performance. The mild (55) cut-point on the PROMIS-A-CAT had sensitivity of 0.59 and specificity of 0.79 (Table 3) and the PROMIS-A-SF had higher sensitivity (0.67) and identical specificity (0.79). At the moderate cut-point (65) both PROMIS measures had sensitivity of 0.19 and specificity of 0.97.

At the recommended cut-point (55) for mild anxiety symptoms, the sensitivity of the PROMIS-A-CAT (0.59) was lower than HADS-A and GAD-7, similar to PSYCH-6, and higher than DT, DASS-A and DASS-S (Table 3). Sensitivity of the PROMIS-A-SF (0.67) was comparable to GAD-7, slightly higher than HADS-A, and higher than PSYCH-6, DT, DASS-A and DASS-S. The PROMIS-A-SF had the highest NPV (0.86), similar to the GAD-7, slightly higher than HADS-A and PSYCH-6, which were similar to PROMIS-A-CAT and higher than the DT, DASS-A and DASS-S (Table 3). Thus, the ability of the PROMIS measures to detect anxiety at the proposed mild cut-points varied, with the PROMIS-A-SF comparable to the GAD-7 and HADS-A, but better than the other legacy measures and the PROMIS-A-CAT.

At the proposed moderate cut-point, the specificity of both PROMIS measures (0.97) was higher than those legacy measures with a moderate category (HADS-A, GAD-7, DASS-A and DASS-S), as was the PPV (0.71). However, the sensitivity of the PROMIS measures at the proposed moderate cut-point was very low (both 0.19) and lower than all legacy measures except the DASS-S.

Alternate cut-points

Youden’s Index was maximised ($J=0.53$) at a cut-point of 53 on the PROMIS-A-CAT with sensitivity of 0.81 and specificity of 0.72. For the PROMIS-A-SF, Youden’s Index was maximised ($J=0.47$) over three cut-points (52–54). Sensitivity (0.78) and specificity (0.70) were identical for scores of 52 and 53 while a cut-point of 54 on the PROMIS-A-SF had lower sensitivity (0.72) and higher specificity (0.75). Since there was little to recommend one cut-point over another, the full results for a cut-point of 53 are reported in Table 3, to match the CAT.

A sensitivity analysis was conducted, which included participants with subthreshold anxiety in the reference standard. This included an additional four cases of Any Anxiety Disorder. The results of the study were not substantially changed. AUCs of the PROMIS measures were increased by 0.01–0.03. Sensitivity and specificity were improved by 0.01–0.02. PPV showed an improvement of 0.04–0.1, with a concomitant decrease in NPV (0.01–0.05) which reflects the changed prevalence of anxiety in

---

**Table 1** Sample characteristics (n = 132)

| Variable                      | n   | %   |
|-------------------------------|-----|-----|
| Female                        | 91  | 69  |
| Marital status                |     |     |
| Married/living as married     | 90  | 68  |
| Separated/divorced/widowed/never married | 42  | 32  |
| Time since diagnosis          |     |     |
| 0–12 months                   | 49  | 37  |
| 13–24 months                  | 30  | 23  |
| More than 24 months           | 53  | 40  |
| Cancer stage                  |     |     |
| Early                         | 19  | 14  |
| Stage 2 or 3                  | 30  | 23  |
| Advanced                      | 23  | 15  |
| Could not determine from self-report | 63  | 48  |
| Cancer type                   |     |     |
| Breast                        | 59  | 45  |
| Haematological                | 18  | 13  |
| Colorectal                     | 16  | 12  |
| Lung                          | 13  | 10  |
| Other                         | 26  | 20  |
| SCID diagnosis                |     |     |
| Generalised anxiety disorder  | 15  | 11  |
| Specific phobia               | 13  | 10  |
| Social phobia                 | 11  | 8   |
| Post-traumatic stress disorder| 3   | 2   |
| Agoraphobia without panic     | 3   | 2   |
| Panic disorder                | 2   | 2   |
| Obsessive compulsive disorder | 2   | 2   |
| Any anxiety disorder          | 37  | 28  |

**Table 2** Area under the curve (AUC) for each measure versus diagnosis of any anxiety disorder using the structured clinical interview for DSM disorders (SCID)

| Measure                      | AUC (95% CI) |
|------------------------------|--------------|
| PROMIS-A-CAT T score         | 82 (73–90)   |
| PROMIS-A-SF T score          | 80 (71–89)   |
| GAD-7                        | 84 (77–91)   |
| HADS-A                       | 79 (70–89)   |
| PSYCH-6                      | 79 (70–89)   |
| DASS-S                       | 77 (68–86)   |
| DASS-A                       | 72 (62–82)   |
| DT                           | 72 (62–82)   |

n = 122 with all measures

(0.84) was also in the good range while the AUC for all other legacy measures fell into the ‘useful’ range (0.72 to 0.79).
the sample. Youden’s Index increased by 0.01-0.02 with optimum cut-off points being 1–2 points lower.

Convergent validity

Correlation with legacy measures

Statistically significant ($p<0.001$) correlations were obtained between the PROMIS anxiety measures and all legacy measures (Table 4). Both PROMIS measures displayed strong correlations with the HADS-A, DASS-S and GAD-7. Moderate correlations were observed between the two PROMIS anxiety measures and DASS-A, DT and PSYCH-6.

PROMIS-A-CAT functioning

T-scores on the PROMIS-A-CAT ranged from 33–75 with mean = 50.8 and standard deviation (SD) = 9.3. Patients with Any Anxiety Disorder had a significantly higher mean T-score on the PROMIS-A-CAT (57.1, SD = 8.3) than those without (48.3, SD = 8.5) ($t = −5.4$, $df = 129$, $p < 0.001$). Using proposed severity levels for the PROMIS-A-CAT [28], most patients (67.4%, $n = 89$), scored in the normal (no-anxiety) range, with 25.0% ($n = 32$) in the mild, 6.8% ($n = 9$) in the moderate and one participant (0.8%) in the severe range.

The mean number of items answered on the PROMIS-A-CAT was 6.4 (range 3–12). Almost half (45.8%, $n = 60$) the participants answered six items on the PROMIS-A-CAT. A further quarter (24.4%, $n = 32$) answered 3–4 items and 14.5% ($n = 19$) completed the full 12 items (Table 5). Participants with Any Anxiety Disorder answered slightly fewer items (mean = 5.7, SD = 1.6) than those without an anxiety disorder (mean = 6.7, SD = 2.9) ($t = 2.1$, $df = 129$, $p = .04$) (Table 5).

PROMIS-A-SF T-scores ranged from 36–74 with mean = 50.6 and SD = 9.2. Patients with Any Anxiety Disorder had a significantly higher mean T-score on the PROMIS-A-SF (56.9, SD = 8.1) than those without (48.1, SD = 8.4) ($t(126) = −5.4$, $p < .001$).
This study confirmed the convergent and criterion validity of two PROMIS anxiety measures, PROMIS-A-CAT and PROMIS-A-SF, by comparing them with four legacy measures of anxiety and two legacy measures of general emotional distress, and against the reference standard SCID for Any Anxiety Disorder in an oncology outpatient sample. It also described how the PROMIS-A-CAT performed in an oncology population, in terms of number of items presented and mean T-scores for those with and without a diagnosis of Any Anxiety Disorder.

**Discussion**

This study confirmed the convergent and criterion validity of two PROMIS anxiety measures, PROMIS-A-CAT and PROMIS-A-SF, by comparing them with four legacy measures of anxiety and two legacy measures of general emotional distress, and against the reference standard SCID for Any Anxiety Disorder in an oncology outpatient sample. It also described how the PROMIS-A-CAT performed in an oncology population, in terms of number of items presented and mean T-scores for those with and without a diagnosis of Any Anxiety Disorder.

**Criterion validity**

Criterion validity of both PROMIS anxiety measures was confirmed, with good AUC (CAT = 0.82, SF = 0.80), that was comparable to or better than all legacy measures (0.72–0.84). Five similar validation studies [18–22] in other health conditions, also found that the PROMIS-A-SF had good AUC (0.80–0.86), comparable to or better than the GAD-7 and HADS-A.

**Cut-points**

At the recommended cut-point for mild anxiety (55), the sensitivity and NPV of the PROMIS-A-SF was comparable to the best-performing legacy measures (GAD-7 and HADS-A), followed by the PROMIS-A-CAT. Overall, however, sensitivity (<.67) and NPV (<.86) were relatively low. The optimum cut-point, using Youden’s index, was 53 on the PROMIS-A-CAT and 52–54 on the PROMIS-A-SF. Of four prior PROMIS-A-SF validation studies, two identified similar cut-points (54.3 [20] and 55.4 [21]) and two identified higher cut-points of 59.4 [19] and 59.9 [18].

Several factors may underpin the different findings among studies comparing the SCID, PROMIS-A-SF, HADS-A and GAD-7. Firstly, the studies covered a diverse range of medical issues (heart failure, MS,
inflammatory bowel disease, rheumatoid arthritis and cancer). Thus, differences in results may reflect genuine differences between these illnesses and the need to adapt cut-points for particular illness groups. Methodological differences may also be important. In particular, reference standards varied somewhat, with some studies using GAD and others using Any Anxiety Disorder. Further, Any Anxiety Disorder included different diagnostic groups across studies. For example, Fischer [18] excluded PTSD and OCD while we included these diagnoses and Marrie [20] included “anxiety due to general medical condition” and “due to substance use” where we did not. Further research is needed to establish optimum cut-points across illness groups, ideally with standardised reference conditions and consideration of specific anxiety diagnoses.

Relative value of PROMIS instruments

Our results indicate that the PROMIS anxiety measures perform similarly to the GAD-7 and HADS-A, in terms of convergent and criterion validity. However, they do not offer any clear advantages in terms of diagnostic accuracy, response burden or costs over these measures. Additionally, there was no clear advantage of the PROMIS-A-CAT over the 7-item PROMIS-A-SF, either in terms of criterion validity or reduced response burden. Perhaps the lower criterion validity of the PROMIS-A-CAT (compared with the PROMIS-A-SF) was affected by reducing the minimum number of items to one (from four). However, the minimum number of items answered in practice was three and this only occurred for 11% (n = 14) of the sample (Table 5). Although a quarter of respondents answered fewer items on the PROMIS-A-CAT than the PROMIS-A-SF (under our study conditions, which allowed a one item minimum), approximately a quarter answered seven or more items, including 15% who answered as many as 12 items (the most of any instrument in the study). Since the PROMIS-A-SF is simpler to administer, some other benefit would be required to encourage use of the PROMIS-A-CAT in clinical, and even research, settings. This may explain why most of the studies of PROMIS anxiety measures in oncology have used the SF and not the CAT. Originators of the PROMIS instruments have also recently noted that CATs only offer marginally improved efficiency over short-form measures in anxiety [25].

Convergent validity

Convergent validity was confirmed by strong correlations between PROMIS anxiety measures and two legacy measures of anxiety (HADS and GAD-7). The lower ('moderate') correlations with measures of general distress (DT and PSYCH) might be expected since they are intended to measure generalised distress rather than specific anxiety disorder symptoms, and these moderate correlations are therefore adequate. The correlations between PROMIS Anxiety measures and the DT and PSYCH were higher than we previously reported between PROMIS depression measures and those instruments [41], perhaps suggesting that general distress conceptually resembles anxiety more closely than depression.

Functioning of the CAT

T scores

The mean T-scores on the PROMIS-A-CAT (50.8, SD 9.33) matched the reference population norm, as did
the PROMIS-A-SF (50.6, SD = 9.2). As 28% of our sample had a clinical diagnosis of Any Anxiety Disorder, we could have expected our mean to be higher. Two other studies that reported CAT T-scores in oncology populations also obtained mean T-scores close to the reference population mean (52.8, SD 9.1) [13] and 47–48 (SD not reported) [14]. The overall mean Anxiety T-score norm was 49.2 (SD 0.2) in one large (n = 5284) American study of people with cancer, using an 11-item SF measure [42]. As no studies have had reference standard measures of clinical anxiety, it is difficult to determine whether anxiety is genuinely comparable to a general population in oncology samples, or whether the algorithm used to calculate T-scores for CAT and SF measures is not optimal for oncology populations.

Respondents with an anxiety disorder had a considerably higher mean T-score than those who did not on both the PROMIS-A-CAT (57, SD = 8.3 vs. 48, SD = 8.5), and the PROMIS-A-SF (57, SD = 8.1 vs. 48, SD = 8.4), confirming the ability of the PROMIS instruments to distinguish between those with anxiety symptoms and those without. Recently published T-Score maps [43] suggest that T-scores around 50 are obtained by those who never experience symptoms and T-scores of 55–60 are obtained by people who experience symptoms rarely or sometimes. Another recent study [44] linked a T-score of 50 to a score of two, on a single item (0–10) rating of anxiety and T-scores of 55–60 to scores of 4–6/10. These studies suggest that a T-score of 50 is indicative of virtually no anxiety symptomatology and a T-score of 55 suggests low level anxiety symptoms. Consequently, it could have been expected that sensitivity of the PROMIS anxiety measures, at a cut-off point of 55, would have been higher than obtained. Overall, these findings suggest the current T-score algorithm, which uses norms for the US general population, may not be optimal for oncology populations, given that 28% of our sample had a clinical diagnosis of Any Anxiety Disorder yet this was not reflected in the mean T-Score of 50. Furthermore, those without a mental health diagnosis in our study and in that of Quach et al. [15] had a mean score of less than 50. Differences for oncology populations have been considered previously, with the development of a PROMIS anxiety instrument specific to oncology (PROMIS_Ca_Bank_v1.0-Anxiety 6-24-2016.pdf), however, this instrument does not appear to have been further adopted (Tran 2021).

**Number of CAT items**

A stated benefit of CAT is reduced response burden through a reduced number of items [11]. We found the CAT did operate as a brief instrument for most participants, terminating for the majority (81.7%) by seven items, with an overall mean of 6.4 items answered. However, we allowed a minimum of one item (maintaining standard pre-specified precision levels) to enable the CAT to use as few items as possible, whereas the standard protocol allows a minimum of four items. The overall response burden of the CAT was not substantially better than the GAD-7 or HADS-A, which also outperformed the CAT on diagnostic statistics.

Respondents with an anxiety disorder completed fewer items on the PROMIS-A-CAT, as we found previously for patients with depression on the PROMIS-D-CAT [23]. This is consistent with CAT discontinuation rules, and has the practical effect of requiring fewer items to confirm the presence of more severe symptoms, and needing more items in the presence of less severe symptoms.

**Strengths and limitations**

Strengths include comparison with legacy measures along with structured clinical interview and blending of clinical interviewers to responses on the self-report measures. Additionally, only one other located study reported using the PROMIS-CAT software in oncology. Most studies using PROMIS measures in oncology have used SF measures. Although the sample size was reasonable, as was the number of participants with “Any Anxiety Disorder”, there is considerable heterogeneity in symptoms across anxiety disorders and further study of validity in specific sub-types of anxiety is warranted. Some types of anxiety disorders (social phobia, obsessive–compulsive disorder) may affect a person’s response to having cancer, but may not be the intended target of psycho-social programs attempting to address cancer-related anxiety. The study involved a time commitment from participants of one to two hours, which may have contributed to the relatively low consent rate (41%), so the sample may not be representative of all oncology patients in our clinic. However, to bias our results and conclusions, any resultant sample selection would have to affect the relationship between responses to the diagnostic interview and the self-report survey questions. Presenting the measures in a random order would have avoided potential order effects; as discussed previously [23], we believe there was limited likelihood of order effects. Completion rates for the measures were uniformly high (98–100%), and were not lower for measures presented later in the assessment, indicating there was no order-induced respondent fatigue. Formal measures of inter-rater reliability were not obtained; however, the SCID interview was administered by experienced psychologists, trained according to SCID protocol and the structured nature of the interview reduces variation.
Conclusion
This study demonstrated the criterion validity of the PROMIS-A-CAT and PROMIS-A-SF measures relative to structured clinical interview (SCID) and convergent validity relative to several legacy measures in an oncology sample. The PROMIS measures had convergent and criterion validity similar to, but no better than, two well-established legacy measures of anxiety (GAD-7 and HADS-A), and somewhat better than the other legacy measures (DASS-A, DASS-S, DT, PSYCH-6). More work is needed to determine optimum cut-points on PROMIS anxiety measures and whether the T-score algorithm, based on US population norms, is optimal for oncology samples. Contrary to expectations, the PROMIS-A-SF demonstrated slight advantages over the PROMIS-A-CAT in terms of diagnostic accuracy and response burden.

Reporting guidelines
The manuscript conforms to the guideline for reporting Diagnostic Accuracy Studies: STARD.

Acknowledgements
We would like to thank our Psychologist interviewers and all of the participants who gave so generously of their time. Thanks also to Erin Forbes for assistance with manuscript preparation.

Author contributions
All authors contributed substantially to the conception and design of the study (including choice of instruments), interpretation of results, and contributed to the final manuscript. Additionally, BB trained the psychologist interviewers; KC ran the study, including overseeing data collection; CO advised on statistical analysis; and CO and KC performed the statistical analysis. All authors have approved the manuscript for publication.

Funding
This study was funded by Calvary Mater Newcastle (Grant No. 11-09) and the Centre for Translational Neuroscience and Mental Health of the University of Newcastle (Australia) provided funding for statistical analysis. Professor King is supported by the Australian Government through Cancer Australia. Dr Lambert was initially supported by a National Health and Medical Research Council Research Fellowship (APP1012869) during data collection and by an FRQ S Junior 1 Research Scholar Award subsequently.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or National Research Committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The project was approved by the Hunter Area Research Ethics Committee (Reference number 09/11/185/09).

Consent to participate
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Psycho-Oncology Service, Calvary Mater Newcastle, Waratah, NSW, Australia. 2. College of Health, Medicine and Wellbeing, School of Medicine and Population Health, University of Newcastle, Callaghan, NSW, Australia. 3. Ingram School of Nursing, McGill University & St. Mary’s Research Centre, Montreal, QC, Canada. 4. Clinical Research Design, Information Technology and Statistical Support (CREDiTSS) Hunter Medical Research Institute, New Lambton Heights, NSW, Australia. 5. Cancer & Molecular Medicine, University of Leicester, Leicester, UK. 6. Faculty of Science, School of Psychology, University of Sydney, Level 6 North, Chris O’Brien Lifehouse (C392), Camperdown, NSW 2006, Australia.

Received: 13 December 2021 Accepted: 5 June 2022
Published online: 20 July 2022

References
1. Institute of Medicine Committee on Psychosocial Services to Cancer Patients/Families in a Community S (2008) Cancer care for the whole patient: meeting psychosocial health needs. Adler NE, Page A (eds). National Academies Press (US): National Academy of Sciences, Washington, DC
2. Mitchell AJ, Ferguson DW, Gill J, Paul J, Symonds P (2013) Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol 14(8):721–732
3. Linden W, Vodermaier A, Mackenzie R, Greig D (2012) Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord 141(2–3):343–351
4. Carlson LE, Angen M, Cullum J, Goody E, Koopmans J, Lamont L et al (2004) High levels of untreated distress and fatigue in cancer patients. Br J Cancer 90(12):2297–2304
5. BrintzenhofeSzoc KM, Levin TT, Li Y, Kissane DW, Zabora JR (2009) Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics 50(4):383–391
6. Zabora J, BrintzenhofeSzoc K, Curkovic B, Hooker C, Piantadosi S (2001) The prevalence of psychological distress by cancer site. Psychooncology 10(1):19–28
7. Traeger L, Greer JA, Fernandez-Robles C, Temel JS, Pirl WF (2012) Evidence-based treatment of anxiety in patients with cancer. J Clin Oncol 30(11):1197–1205
8. Roy-Byrne PP, Davidson KW, Kessler RC, Asmundson GJ, Goodwin RD, Kubzansky L et al (2008) Anxiety disorders and comorbid medical illness. Gen Hosp Psychiatry 30(3):208–225
9. Mitchell AJ (2007) Pooled results from 38 analyses of the accuracy of distress thermometer and other ultra-short methods of detecting cancer-related mood disorders. J Clin Oncol 25(29):4670–4681
10. Cella D, Gershon R, Bass M, Rothrock N (2017) Assessment centre user manual
11. Chai SW, Reise SP, Pilkonis PA, Hays RD, Cella D (2010) Efficiency of static and computer adaptive short forms compared to full-length measures of depressive symptoms. Qual Life Res 19(1):125–136
12. Tran TXM, Park J, Lee J, Jung YS, Chang Y, Cho H (2021) Utility of the patient-reported outcomes measurement information system (PROMIS) to measure primary health outcomes in cancer patients: a systematic review. Support Care Cancer 29(4):1723–1739
13. Wagner LI, Schink J, Bass M, Patel S, Diaz MV, Rothrock N et al (2015) Bringing PROMIS to practice: brief and precise symptom screening in ambulatory cancer care. Cancer 121(6):927–934
14. Stone AA, Broderick JE, Junghaenel DJ, Schneider S, Schwartz JE (2016) PROMIS fatigue, pain intensity, pain interference, pain behavior, physical function, depression, anxiety, and anger scales demonstrate ecological validity. J Clin Epidemiol 74:194–206
15. Quach CW, Langer MM, Chen RC, Thissen D, Usinger DS, Emerson MA et al (2016) Reliability and validity of PROMIS measures administered by telephone interview in a longitudinal localized prostate cancer study. Qual Life Res 25(11):2811–2823
16. Wilford J, Osann K, Hsieh S, Monk B, Nelson E, Wenzel L (2018) Validation of PROMIS emotional distress short form scales for cervical cancer. Gynecol Oncol 151(1):111–116
17. Sikorski A, Victorson D, O'Connor P, Hankin V, Safikhani A, Crane T et al (2018) PROMIS and legacy measures compared in a supportive care intervention for breast cancer patients and caregivers: experience from a randomized trial. Psychooncology 27(9):2265–2273
18. Fischer HF, Klug C, Roepke K, Blozik E, Edelmann F, Eisele M et al (2014) Screening for mental disorders in heart failure patients using computer-adaptive tests. Qual Life Res 23(5):1609–1618
19. Bernstein CN, Zhang L, Lix LM, Graff LA, Walker JR, Fisk JD et al (2018) The validity and reliability of screening measures for depression and anxiety disorders in inflammatory bowel disease. Inflamm Bowel Dis. https://doi.org/10.1093/ibd/zyo068
20. Marrie RA, Zhang L, Lix LM, Graff LA, Walker JR, Fisk JD et al (2018) The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis. Mult Scler Relat Disord 2019–15
21. Hitchon CA, Zhang L, Peschken CA, Lix LM, Graff LA, Fisk JD et al (2019) The validity and reliability of screening measures for depression and anxiety disorders in rheumatoid arthritis. Arthritis Care Res. https://doi.org/10.1002acr.24011
22. van Bebber J, Flens G, Wigman JT W, de Beurs E, Sytema S, Wurdenink L et al (2018) Application of the patient-reported outcomes measurement information system (PROMIS) item parameters for anxiety and depression in the Netherlands. Int J Methods Psychiatr Res 27(4):e1744
23. Clover K, Lambert SD, Oldmeadow C, Britton B, King MT, Mitchell AJ et al (2018) PROMIS depression measures perform similarly to legacy measures relative to a structured diagnostic interview for depression in cancer patients. Qual Life Res 27(5):1357–1367
24. Clover KA, Rogers KM, Britton B, Oldmeadow C, Attila J, Carter GL (2017) Reduced prevalence of pain and distress during 4 years of screening with QUICATOUCH in Australian oncology patients. Eur J Cancer Care. https://doi.org/10.1111/ecc.12636
25. Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S et al (2010) The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. J Clin Epidemiol 63(11):1179–1194
26. Health Measures Accessed Nov 2017 [Available from: http://www.healthmeasures.net]
27. PROMIS Patient Reported Outcomes Measurement Information System Accessed Nov 2013 [Available from: PROMIS (healthmeasures.net) Available from: http://nhipromis.org/measures]
28. Cella D, Choi S, Garcia S, Cook KF, Rosenbloom S, Lai J et al (2014) Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment. Qual Life Res 23(10):2651–2661
29. Spitzer RL, Kroenke K, Williams JB, Lowe B (2006) A brief measure for depression and anxiety, among oncology outpatients. Aust N Z J Psychiatry 40(4):344–345
30. Kroenke K, Spitzer RL, Williams JB, Lowe B, Danielson PA, Emsley RA et al (2009) The validity and reliability of screening measures for depression and anxiety, among oncology outpatients. Aust N Z J Psychiatry 43(7):682–688
31. Mitchell AJ, Meader N, Symonds P (2010) Diagnostic validity of the hospital anxiety and depression scale (HADS) in cancer and palliative settings: a meta-analysis. J Affect Disord 126(3):335–348
32. Vodermaier A, Millman RD (2011) Accuracy of the hospital anxiety and depression scale as a screening tool in cancer patients: a systematic review and meta-analysis. Support Care Cancer 19(12):1899–1908
33. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370
34. Lovibond PF, Lovibond SH (1995) Manual for the depression anxiety stress scales, 2nd edn. Psychology Foundation, Sydney
35. Clover K, Leigh Carter G, Adams C, Hickie I, Davenport T (2009) Concurrent validity of the PSYCH-6, a very short scale for detecting anxiety and depression, among oncology outpatients. Aust N Z J Psychiatry 43(7):682–688
36. Network NCC (2003) Distress management. Clinical practice guidelines. J Natl Compr Canc Netw 1(3):344–374
37. First MB, Gibbon M, Spitzer RL, B-WJ (2002) User’s guide for the structured clinical interview for DSM-IV-TR axis I disorders-research version (SCID-I for DSM-IV-TR), November 2002 Revision. New York State Psychiatric Institute, New York
38. Swets JA (1988) Measuring the accuracy of diagnostic systems. Science 240(4857):1285–1293
39. Smits N (2010) A note on Youden’s J and its cost ratio. BMC Med Res Methodol 10:89
40. Maxim LD, Niebo R, Utell MJ (2014) Screening tests: a review with examples. Inhalation Toxicol 26(13):811–828
41. Dancy C, Reidy J (2004) Statistics without maths for psychology. Pearson Education Limited, Harlow
42. Jensen RE, Potosky AL, Moopin CM, Lobo T, Cella D, Hahn EA et al (2017) United States population-based estimates of patient-reported outcomes measurement information system symptom and functional status reference values for individuals with cancer. J Clin Oncol 35(17):1913–1920
43. Rothrock NE, Amtmann D, Cook KF (2020) Development and validation of an interpretive guide for PROMIS scores. J Patient Rep Outcomes 4(1):16
44. Lee MK, Schalet BD, Cella D, Yost KJ, Dueck AC, Novotny PJ et al (2020) Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Patient Rep Outcomes 4(1):106

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.